ETFs & Funds
"off label" for men with very late stage, metastatic, and chemotherapy-resistant prostate cancer too.'
that's pretty good thank's for the I see this one going higher
Add a reply...
Latest StockTalks »
people get EXEL breaking news and analysis by email alert.
Get email alerts on EXEL »
Get latest price
From other sites
Exelixis' Cabozantinib Positive in Renal Cell Carcinoma Study
at Zacks.com (Feb 2, 2016)
Exelixis's Cabozantinib Granted Priority Review in the U.S.
at Zacks.com (Jan 29, 2016)
Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
at Zacks.com (Nov 26, 2015)
Roche & Exelixis Announce Positive Data on Cotellic & Zelboraf
at Zacks.com (Nov 23, 2015)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
at Zacks.com (Nov 11, 2015)